CA2649701A1 - Utilisation de composes organiques - Google Patents

Utilisation de composes organiques Download PDF

Info

Publication number: CA2649701A1
Authority: CA; Canada
Prior art keywords: disease; diabetes; agonist; err; treatment
Prior art date: 2006-05-03
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002649701A

Other languages

English (en)

Inventor

Shamina M. Rangwala

Susan C. Stevenson

Zhidan Wu

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Novartis AG

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-05-03

Filing date

2007-05-02

Publication date

2007-11-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38477124&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2649701(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-05-02 Application filed by Individual filed Critical Individual

2007-11-15 Publication of CA2649701A1 publication Critical patent/CA2649701A1/fr

Status Abandoned legal-status Critical Current

Links

150000002894 organic compounds Chemical class 0.000 title description 2
239000000556 agonist Substances 0.000 claims abstract description 82
208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract description 45
206010012601 diabetes mellitus Diseases 0.000 claims abstract description 27
206010033307 Overweight Diseases 0.000 claims abstract description 23
208000024827 Alzheimer disease Diseases 0.000 claims abstract description 22
208000015122 neurodegenerative disease Diseases 0.000 claims abstract description 20
150000003839 salts Chemical class 0.000 claims abstract description 20
230000002265 prevention Effects 0.000 claims abstract description 19
208000001145 Metabolic Syndrome Diseases 0.000 claims abstract description 18
201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims abstract description 18
230000037080 exercise endurance Effects 0.000 claims abstract description 17
230000004770 neurodegeneration Effects 0.000 claims abstract description 17
208000032928 Dyslipidaemia Diseases 0.000 claims abstract description 16
208000023105 Huntington disease Diseases 0.000 claims abstract description 16
208000017170 Lipid metabolism disease Diseases 0.000 claims abstract description 16
208000008589 Obesity Diseases 0.000 claims abstract description 16
230000006872 improvement Effects 0.000 claims abstract description 16
235000020824 obesity Nutrition 0.000 claims abstract description 16
206010022489 Insulin Resistance Diseases 0.000 claims abstract description 15
208000018737 Parkinson disease Diseases 0.000 claims abstract description 15
208000016097 disease of metabolism Diseases 0.000 claims abstract description 15
208000030159 metabolic disease Diseases 0.000 claims abstract description 15
241001465754 Metazoa Species 0.000 claims description 55
238000003556 assay Methods 0.000 claims description 32
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 22
238000002866 fluorescence resonance energy transfer Methods 0.000 claims description 22
201000010099 disease Diseases 0.000 claims description 21
238000000034 method Methods 0.000 claims description 19
239000008194 pharmaceutical composition Substances 0.000 claims description 17
239000003814 drug Substances 0.000 claims description 13
238000004519 manufacturing process Methods 0.000 claims description 6
239000003937 drug carrier Substances 0.000 claims description 5
IKPPIUNQWSRCOZ-WOJGMQOQSA-N GSK 4716 Chemical group C1=CC(C(C)C)=CC=C1\C=N\NC(=O)C1=CC=C(O)C=C1 IKPPIUNQWSRCOZ-WOJGMQOQSA-N 0.000 claims 1
WLKOCYWYAWBGKY-UYRXBGFRSA-N n-[(z)-[4-(diethylamino)phenyl]methylideneamino]-4-hydroxybenzamide Chemical compound C1=CC(N(CC)CC)=CC=C1\C=N/NC(=O)C1=CC=C(O)C=C1 WLKOCYWYAWBGKY-UYRXBGFRSA-N 0.000 claims 1
150000001875 compounds Chemical class 0.000 description 52
210000004369 blood Anatomy 0.000 description 39
239000008280 blood Substances 0.000 description 39
230000014509 gene expression Effects 0.000 description 39
108090000623 proteins and genes Proteins 0.000 description 25
230000000694 effects Effects 0.000 description 24
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 21
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 20
241000699670 Mus sp. Species 0.000 description 19
239000003981 vehicle Substances 0.000 description 18
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 17
241000699666 Mus <mouse, genus> Species 0.000 description 17
239000008103 glucose Substances 0.000 description 17
239000000523 sample Substances 0.000 description 17
238000004458 analytical method Methods 0.000 description 15
230000037396 body weight Effects 0.000 description 15
WLKOCYWYAWBGKY-CPNJWEJPSA-N n-[(e)-[4-(diethylamino)phenyl]methylideneamino]-4-hydroxybenzamide Chemical compound C1=CC(N(CC)CC)=CC=C1\C=N\NC(=O)C1=CC=C(O)C=C1 WLKOCYWYAWBGKY-CPNJWEJPSA-N 0.000 description 14
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 13
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 12
210000004027 cell Anatomy 0.000 description 12
108020004067 estrogen-related receptors Proteins 0.000 description 12
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 12
238000005259 measurement Methods 0.000 description 12
108020001756 ligand binding domains Proteins 0.000 description 11
201000009104 prediabetes syndrome Diseases 0.000 description 11
102100030497 Cytochrome c Human genes 0.000 description 10
108010075031 Cytochromes c Proteins 0.000 description 10
208000002705 Glucose Intolerance Diseases 0.000 description 10
241000282414 Homo sapiens Species 0.000 description 10
101000851700 Homo sapiens Steroid hormone receptor ERR1 Proteins 0.000 description 10
102100036832 Steroid hormone receptor ERR1 Human genes 0.000 description 10
230000004044 response Effects 0.000 description 10
208000016261 weight loss Diseases 0.000 description 10
230000004580 weight loss Effects 0.000 description 10
231100000673 dose–response relationship Toxicity 0.000 description 9
229940079593 drug Drugs 0.000 description 9
102000004169 proteins and genes Human genes 0.000 description 9
230000029058 respiratory gaseous exchange Effects 0.000 description 9
239000004480 active ingredient Substances 0.000 description 8
235000014113 dietary fatty acids Nutrition 0.000 description 8
229930195729 fatty acid Natural products 0.000 description 8
239000000194 fatty acid Substances 0.000 description 8
150000004665 fatty acids Chemical class 0.000 description 8
239000000203 mixture Substances 0.000 description 8
238000012360 testing method Methods 0.000 description 8
108010030844 2-methylcitrate synthase Proteins 0.000 description 7
108010071536 Citrate (Si)-synthase Proteins 0.000 description 7
102000006732 Citrate synthase Human genes 0.000 description 7
239000002253 acid Substances 0.000 description 7
239000003446 ligand Substances 0.000 description 7
239000000126 substance Substances 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
102000004877 Insulin Human genes 0.000 description 6
108090001061 Insulin Proteins 0.000 description 6
238000011529 RT qPCR Methods 0.000 description 6
230000004913 activation Effects 0.000 description 6
238000007792 addition Methods 0.000 description 6
229910002092 carbon dioxide Inorganic materials 0.000 description 6
238000002474 experimental method Methods 0.000 description 6
229940125396 insulin Drugs 0.000 description 6
230000002438 mitochondrial effect Effects 0.000 description 6
238000007410 oral glucose tolerance test Methods 0.000 description 6
108090000765 processed proteins & peptides Proteins 0.000 description 6
238000002965 ELISA Methods 0.000 description 5
229910052693 Europium Inorganic materials 0.000 description 5
102000017946 PGC-1 Human genes 0.000 description 5
108700038399 PGC-1 Proteins 0.000 description 5
239000000872 buffer Substances 0.000 description 5
239000001569 carbon dioxide Substances 0.000 description 5
229940011871 estrogen Drugs 0.000 description 5
239000000262 estrogen Substances 0.000 description 5
OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 5
230000037406 food intake Effects 0.000 description 5
235000012631 food intake Nutrition 0.000 description 5
239000002207 metabolite Substances 0.000 description 5
230000003647 oxidation Effects 0.000 description 5
238000007254 oxidation reaction Methods 0.000 description 5
230000001590 oxidative effect Effects 0.000 description 5
230000010627 oxidative phosphorylation Effects 0.000 description 5
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 5
108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
108091003079 Bovine Serum Albumin Proteins 0.000 description 4
102100031855 Estrogen-related receptor gamma Human genes 0.000 description 4
206010020772 Hypertension Diseases 0.000 description 4
206010056997 Impaired fasting glucose Diseases 0.000 description 4
238000012754 cardiac puncture Methods 0.000 description 4
235000012000 cholesterol Nutrition 0.000 description 4
230000003081 coactivator Effects 0.000 description 4
239000000825 pharmaceutical preparation Substances 0.000 description 4
-1 phenolic acyl hydrazones Chemical class 0.000 description 4
230000000069 prophylactic effect Effects 0.000 description 4
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
239000003826 tablet Substances 0.000 description 4
PKYCWFICOKSIHZ-UHFFFAOYSA-N 1-(3,7-dihydroxyphenoxazin-10-yl)ethanone Chemical compound OC1=CC=C2N(C(=O)C)C3=CC=C(O)C=C3OC2=C1 PKYCWFICOKSIHZ-UHFFFAOYSA-N 0.000 description 3
102100038595 Estrogen receptor Human genes 0.000 description 3
108010010234 HDL Lipoproteins Proteins 0.000 description 3
102000015779 HDL Lipoproteins Human genes 0.000 description 3
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 3
241000124008 Mammalia Species 0.000 description 3
108020005196 Mitochondrial DNA Proteins 0.000 description 3
102100040200 Mitochondrial uncoupling protein 2 Human genes 0.000 description 3
101710112393 Mitochondrial uncoupling protein 2 Proteins 0.000 description 3
102100040216 Mitochondrial uncoupling protein 3 Human genes 0.000 description 3
101710112412 Mitochondrial uncoupling protein 3 Proteins 0.000 description 3
229940124158 Protease/peptidase inhibitor Drugs 0.000 description 3
210000000577 adipose tissue Anatomy 0.000 description 3
150000001413 amino acids Chemical class 0.000 description 3
230000003321 amplification Effects 0.000 description 3
230000027455 binding Effects 0.000 description 3
230000023555 blood coagulation Effects 0.000 description 3
229940098773 bovine serum albumin Drugs 0.000 description 3
238000005119 centrifugation Methods 0.000 description 3
239000002299 complementary DNA Substances 0.000 description 3
238000002425 crystallisation Methods 0.000 description 3
230000008025 crystallization Effects 0.000 description 3
230000006378 damage Effects 0.000 description 3
238000013229 diet-induced obese mouse Methods 0.000 description 3
108010038795 estrogen receptors Proteins 0.000 description 3
108091008557 estrogen-related receptor gamma Proteins 0.000 description 3
229960002897 heparin Drugs 0.000 description 3
229920000669 heparin Polymers 0.000 description 3
230000006698 induction Effects 0.000 description 3
229910052744 lithium Inorganic materials 0.000 description 3
230000004048 modification Effects 0.000 description 3
238000012986 modification Methods 0.000 description 3
239000003068 molecular probe Substances 0.000 description 3
238000003199 nucleic acid amplification method Methods 0.000 description 3
108090000629 orphan nuclear receptors Proteins 0.000 description 3
102000004164 orphan nuclear receptors Human genes 0.000 description 3
230000036284 oxygen consumption Effects 0.000 description 3
238000007911 parenteral administration Methods 0.000 description 3
239000000137 peptide hydrolase inhibitor Substances 0.000 description 3
239000002953 phosphate buffered saline Substances 0.000 description 3
239000000651 prodrug Substances 0.000 description 3
229940002612 prodrug Drugs 0.000 description 3
238000011160 research Methods 0.000 description 3
239000002904 solvent Substances 0.000 description 3
238000005556 structure-activity relationship Methods 0.000 description 3
239000000758 substrate Substances 0.000 description 3
150000003626 triacylglycerols Chemical class 0.000 description 3
230000004102 tricarboxylic acid cycle Effects 0.000 description 3
208000004611 Abdominal Obesity Diseases 0.000 description 2
210000002237 B-cell of pancreatic islet Anatomy 0.000 description 2
BMZRVOVNUMQTIN-UHFFFAOYSA-N Carbonyl Cyanide para-Trifluoromethoxyphenylhydrazone Chemical compound FC(F)(F)OC1=CC=C(NN=C(C#N)C#N)C=C1 BMZRVOVNUMQTIN-UHFFFAOYSA-N 0.000 description 2
208000024172 Cardiovascular disease Diseases 0.000 description 2
206010065941 Central obesity Diseases 0.000 description 2
102100027896 Cytochrome b-c1 complex subunit 7 Human genes 0.000 description 2
108020004414 DNA Proteins 0.000 description 2
206010012289 Dementia Diseases 0.000 description 2
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 2
102000001301 EGF receptor Human genes 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
206010018429 Glucose tolerance impaired Diseases 0.000 description 2
101001060428 Homo sapiens Cytochrome b-c1 complex subunit 7 Proteins 0.000 description 2
101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 description 2
108010007622 LDL Lipoproteins Proteins 0.000 description 2
102000007330 LDL Lipoproteins Human genes 0.000 description 2
102000015494 Mitochondrial Uncoupling Proteins Human genes 0.000 description 2
108010050258 Mitochondrial Uncoupling Proteins Proteins 0.000 description 2
101100275485 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cox-4 gene Proteins 0.000 description 2
102000004966 Nuclear Receptor Coactivator 1 Human genes 0.000 description 2
108090001146 Nuclear Receptor Coactivator 1 Proteins 0.000 description 2
101150014691 PPARA gene Proteins 0.000 description 2
229930182555 Penicillin Natural products 0.000 description 2
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
206010039966 Senile dementia Diseases 0.000 description 2
208000006011 Stroke Diseases 0.000 description 2
238000000692 Student's t-test Methods 0.000 description 2
208000037063 Thinness Diseases 0.000 description 2
102000004142 Trypsin Human genes 0.000 description 2
108090000631 Trypsin Proteins 0.000 description 2
239000012190 activator Substances 0.000 description 2
239000013543 active substance Substances 0.000 description 2
239000012131 assay buffer Substances 0.000 description 2
230000000740 bleeding effect Effects 0.000 description 2
230000036772 blood pressure Effects 0.000 description 2
210000004899 c-terminal region Anatomy 0.000 description 2
150000001720 carbohydrates Chemical class 0.000 description 2
235000014633 carbohydrates Nutrition 0.000 description 2
239000006285 cell suspension Substances 0.000 description 2
230000004098 cellular respiration Effects 0.000 description 2
238000012512 characterization method Methods 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
208000010877 cognitive disease Diseases 0.000 description 2
238000001514 detection method Methods 0.000 description 2
238000003745 diagnosis Methods 0.000 description 2
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
230000002526 effect on cardiovascular system Effects 0.000 description 2
230000002124 endocrine Effects 0.000 description 2
239000012091 fetal bovine serum Substances 0.000 description 2
239000000446 fuel Substances 0.000 description 2
229940088597 hormone Drugs 0.000 description 2
239000005556 hormone Substances 0.000 description 2
201000001421 hyperglycemia Diseases 0.000 description 2
230000001631 hypertensive effect Effects 0.000 description 2
230000000366 juvenile effect Effects 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
208000027061 mild cognitive impairment Diseases 0.000 description 2
230000004898 mitochondrial function Effects 0.000 description 2
210000003098 myoblast Anatomy 0.000 description 2
229940049954 penicillin Drugs 0.000 description 2
239000003614 peroxisome proliferator Substances 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
230000009467 reduction Effects 0.000 description 2
238000012216 screening Methods 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
241000894007 species Species 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
229960005322 streptomycin Drugs 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
230000009261 transgenic effect Effects 0.000 description 2
230000032258 transport Effects 0.000 description 2
239000012588 trypsin Substances 0.000 description 2
206010048828 underweight Diseases 0.000 description 2
230000003442 weekly effect Effects 0.000 description 2
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
MNULEGDCPYONBU-WMBHJXFZSA-N (1r,4s,5e,5'r,6'r,7e,10s,11r,12s,14r,15s,16s,18r,19s,20r,21e,25s,26r,27s,29s)-4-ethyl-11,12,15,19-tetrahydroxy-6'-[(2s)-2-hydroxypropyl]-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trio Polymers O([C@@H]1CC[C@@H](/C=C/C=C/C[C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)/C=C/C(=O)O[C@H]([C@H]2C)[C@H]1C)CC)[C@]12CC[C@@H](C)[C@@H](C[C@H](C)O)O1 MNULEGDCPYONBU-WMBHJXFZSA-N 0.000 description 1
MNULEGDCPYONBU-DJRUDOHVSA-N (1s,4r,5z,5'r,6'r,7e,10s,11r,12s,14r,15s,18r,19r,20s,21e,26r,27s)-4-ethyl-11,12,15,19-tetrahydroxy-6'-(2-hydroxypropyl)-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Polymers O([C@H]1CC[C@H](\C=C/C=C/C[C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@H](C)[C@@H](O)C(C)C(=O)[C@H](C)[C@H](O)[C@@H](C)/C=C/C(=O)OC([C@H]2C)C1C)CC)[C@]12CC[C@@H](C)[C@@H](CC(C)O)O1 MNULEGDCPYONBU-DJRUDOHVSA-N 0.000 description 1
GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
MNULEGDCPYONBU-YNZHUHFTSA-N (4Z,18Z,20Z)-22-ethyl-7,11,14,15-tetrahydroxy-6'-(2-hydroxypropyl)-5',6,8,10,12,14,16,28,29-nonamethylspiro[2,26-dioxabicyclo[23.3.1]nonacosa-4,18,20-triene-27,2'-oxane]-3,9,13-trione Polymers CC1C(C2C)OC(=O)\C=C/C(C)C(O)C(C)C(=O)C(C)C(O)C(C)C(=O)C(C)(O)C(O)C(C)C\C=C/C=C\C(CC)CCC2OC21CCC(C)C(CC(C)O)O2 MNULEGDCPYONBU-YNZHUHFTSA-N 0.000 description 1
MNULEGDCPYONBU-VVXVDZGXSA-N (5e,5'r,7e,10s,11r,12s,14s,15r,16r,18r,19s,20r,21e,26r,29s)-4-ethyl-11,12,15,19-tetrahydroxy-6'-[(2s)-2-hydroxypropyl]-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Polymers C([C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)/C=C/C(=O)OC([C@H]1C)[C@H]2C)\C=C\C=C\C(CC)CCC2OC21CC[C@@H](C)C(C[C@H](C)O)O2 MNULEGDCPYONBU-VVXVDZGXSA-N 0.000 description 1
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
101150028074 2 gene Proteins 0.000 description 1
MENUYOGJCXAFFU-UHFFFAOYSA-N 2-(phenylhydrazinylidene)propanedinitrile Chemical compound N#CC(C#N)=NNC1=CC=CC=C1 MENUYOGJCXAFFU-UHFFFAOYSA-N 0.000 description 1
101150029102 3.7 gene Proteins 0.000 description 1
DODQJNMQWMSYGS-QPLCGJKRSA-N 4-[(z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1-phenylbut-1-en-2-yl]phenol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 DODQJNMQWMSYGS-QPLCGJKRSA-N 0.000 description 1
MNULEGDCPYONBU-UHFFFAOYSA-N 4-ethyl-11,12,15,19-tetrahydroxy-6'-(2-hydroxypropyl)-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Polymers CC1C(C2C)OC(=O)C=CC(C)C(O)C(C)C(=O)C(C)C(O)C(C)C(=O)C(C)(O)C(O)C(C)CC=CC=CC(CC)CCC2OC21CCC(C)C(CC(C)O)O2 MNULEGDCPYONBU-UHFFFAOYSA-N 0.000 description 1
IKPPIUNQWSRCOZ-UHFFFAOYSA-N 4-hydroxy-n-[(4-propan-2-ylphenyl)methylideneamino]benzamide Chemical compound C1=CC(C(C)C)=CC=C1C=NNC(=O)C1=CC=C(O)C=C1 IKPPIUNQWSRCOZ-UHFFFAOYSA-N 0.000 description 1
101150106774 9 gene Proteins 0.000 description 1
101001073212 Arabidopsis thaliana Peroxidase 33 Proteins 0.000 description 1
241000237519 Bivalvia Species 0.000 description 1
201000004569 Blindness Diseases 0.000 description 1
201000006474 Brain Ischemia Diseases 0.000 description 1
206010008120 Cerebral ischaemia Diseases 0.000 description 1
101150073133 Cpt1a gene Proteins 0.000 description 1
230000004568 DNA-binding Effects 0.000 description 1
206010052804 Drug tolerance Diseases 0.000 description 1
101150033269 ESRRG gene Proteins 0.000 description 1
241000283073 Equus caballus Species 0.000 description 1
238000011771 FVB mouse Methods 0.000 description 1
102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
208000010412 Glaucoma Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
101001123325 Homo sapiens Peroxisome proliferator-activated receptor gamma coactivator 1-beta Proteins 0.000 description 1
101000851696 Homo sapiens Steroid hormone receptor ERR2 Proteins 0.000 description 1
208000019695 Migraine disease Diseases 0.000 description 1
WLKOCYWYAWBGKY-UHFFFAOYSA-N N-[[4-(diethylamino)phenyl]methylideneamino]-4-hydroxybenzamide Chemical compound C1=CC(N(CC)CC)=CC=C1C=NNC(=O)C1=CC=C(O)C=C1 WLKOCYWYAWBGKY-UHFFFAOYSA-N 0.000 description 1
208000028389 Nerve injury Diseases 0.000 description 1
108020005497 Nuclear hormone receptor Proteins 0.000 description 1
102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 1
108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 1
102100028961 Peroxisome proliferator-activated receptor gamma coactivator 1-beta Human genes 0.000 description 1
208000001280 Prediabetic State Diseases 0.000 description 1
206010036631 Presenile dementia Diseases 0.000 description 1
LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
238000002123 RNA extraction Methods 0.000 description 1
208000001647 Renal Insufficiency Diseases 0.000 description 1
108091027981 Response element Proteins 0.000 description 1
101100333774 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) ERR3 gene Proteins 0.000 description 1
102100036831 Steroid hormone receptor ERR2 Human genes 0.000 description 1
108010006785 Taq Polymerase Proteins 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
230000009471 action Effects 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
230000001640 apoptogenic effect Effects 0.000 description 1
235000021407 appetite control Nutrition 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
239000002585 base Substances 0.000 description 1
210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
238000009227 behaviour therapy Methods 0.000 description 1
230000003542 behavioural effect Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
239000000090 biomarker Substances 0.000 description 1
239000002775 capsule Substances 0.000 description 1
230000007211 cardiovascular event Effects 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000003915 cell function Effects 0.000 description 1
239000013592 cell lysate Substances 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
206010008118 cerebral infarction Diseases 0.000 description 1
230000008859 change Effects 0.000 description 1
235000020639 clam Nutrition 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
229940125797 compound 12 Drugs 0.000 description 1
230000001351 cycling effect Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000006866 deterioration Effects 0.000 description 1
238000010586 diagram Methods 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
238000013399 early diagnosis Methods 0.000 description 1
230000027721 electron transport chain Effects 0.000 description 1
229960005309 estradiol Drugs 0.000 description 1
229930182833 estradiol Natural products 0.000 description 1
230000004907 flux Effects 0.000 description 1
235000013305 food Nutrition 0.000 description 1
210000004744 fore-foot Anatomy 0.000 description 1
239000012458 free base Substances 0.000 description 1
235000021588 free fatty acids Nutrition 0.000 description 1
230000006870 function Effects 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
230000004153 glucose metabolism Effects 0.000 description 1
230000002641 glycemic effect Effects 0.000 description 1
239000008187 granular material Substances 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
230000026781 habituation Effects 0.000 description 1
210000002216 heart Anatomy 0.000 description 1
208000019622 heart disease Diseases 0.000 description 1
235000006796 hypocaloric diet Nutrition 0.000 description 1
238000005286 illumination Methods 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000003993 interaction Effects 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
201000006370 kidney failure Diseases 0.000 description 1
238000002372 labelling Methods 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
230000037356 lipid metabolism Effects 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
239000002609 medium Substances 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
206010027599 migraine Diseases 0.000 description 1
230000008437 mitochondrial biogenesis Effects 0.000 description 1
230000006705 mitochondrial oxidative phosphorylation Effects 0.000 description 1
230000006667 mitochondrial pathway Effects 0.000 description 1
238000002156 mixing Methods 0.000 description 1
125000000896 monocarboxylic acid group Chemical group 0.000 description 1
230000004973 motor coordination Effects 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
210000000663 muscle cell Anatomy 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
230000008764 nerve damage Effects 0.000 description 1
102000006255 nuclear receptors Human genes 0.000 description 1
108020004017 nuclear receptors Proteins 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
229930191479 oligomycin Natural products 0.000 description 1
MNULEGDCPYONBU-AWJDAWNUSA-N oligomycin A Polymers O([C@H]1CC[C@H](/C=C/C=C/C[C@@H](C)[C@H](O)[C@@](C)(O)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@@H](C)[C@H](O)[C@@H](C)/C=C/C(=O)O[C@@H]([C@@H]2C)[C@@H]1C)CC)[C@@]12CC[C@H](C)[C@H](C[C@@H](C)O)O1 MNULEGDCPYONBU-AWJDAWNUSA-N 0.000 description 1
229940127017 oral antidiabetic Drugs 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
230000008092 positive effect Effects 0.000 description 1
230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
230000000291 postprandial effect Effects 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
238000012545 processing Methods 0.000 description 1
150000003242 quaternary ammonium salts Chemical class 0.000 description 1
231100000272 reduced body weight Toxicity 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000035806 respiratory chain Effects 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
238000010839 reverse transcription Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
238000005070 sampling Methods 0.000 description 1
238000009738 saturating Methods 0.000 description 1
238000007423 screening assay Methods 0.000 description 1
210000002027 skeletal muscle Anatomy 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
239000012439 solid excipient Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
239000012453 solvate Substances 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
230000008685 targeting Effects 0.000 description 1
238000010998 test method Methods 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
230000036962 time dependent Effects 0.000 description 1
238000004448 titration Methods 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
108091006108 transcriptional coactivators Proteins 0.000 description 1
108091008023 transcriptional regulators Proteins 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
230000003827 upregulation Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Diabetes (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Obesity (AREA)
Hematology (AREA)
Epidemiology (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Endocrinology (AREA)
Psychiatry (AREA)
Emergency Medicine (AREA)
Child & Adolescent Psychology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

CA002649701A 2006-05-03 2007-05-02 Utilisation de composes organiques Abandoned CA2649701A1 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US79722806P	2006-05-03	2006-05-03
US60/797,228		2006-05-03
PCT/US2007/067971 WO2007131005A2 (fr)	2006-05-03	2007-05-02	Utilisation de composés organiques

Publications (1)

Publication Number	Publication Date
CA2649701A1 true CA2649701A1 (fr)	2007-11-15

Family

ID=38477124

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002649701A Abandoned CA2649701A1 (fr)	2006-05-03	2007-05-02	Utilisation de composes organiques

Country Status (13)

Country	Link
US (1)	US20090281191A1 (fr)
EP (1)	EP2015777B1 (fr)
JP (1)	JP2009535425A (fr)
KR (1)	KR20090005137A (fr)
CN (1)	CN101432024A (fr)
AT (1)	ATE477819T1 (fr)
AU (1)	AU2007248112A1 (fr)
BR (1)	BRPI0711174A2 (fr)
CA (1)	CA2649701A1 (fr)
DE (1)	DE602007008553D1 (fr)
MX (1)	MX2008014008A (fr)
RU (1)	RU2008147269A (fr)
WO (1)	WO2007131005A2 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2571875A4 (fr)	2010-05-14	2013-10-30	Dana Farber Cancer Inst Inc	Compositions contraceptives pour les hommes et procédés d'utilisation associés
PL2902030T3 (pl)	2010-05-14	2017-07-31	Dana-Farber Cancer Institute, Inc.	Związki tienotriazolodiazepinowe do leczenia nowotworu
MX354217B (es)	2010-05-14	2018-02-19	Dana Farber Cancer Inst Inc	Composiciones y metodos para el tratamiento de leucemia.
US8962546B2 (en) *	2011-03-01	2015-02-24	Salk Institute For Biological Studies	Modulation of estrogen receptor-related receptor gamma (ERRγ) and uses therefor
EP2683704B1 (fr)	2011-03-08	2014-12-17	Sanofi	Dérivés oxathiazine ramifiés, procédé pour leur préparation, utilisation en tant que médicament, agents pharmaceutiques contenant ces dérivés et leur utilisation
WO2012120056A1 (fr)	2011-03-08	2012-09-13	Sanofi	Dérivés oxathiazine tétra-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
US8828994B2 (en)	2011-03-08	2014-09-09	Sanofi	Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2766349B1 (fr)	2011-03-08	2016-06-01	Sanofi	Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation
EP2683699B1 (fr)	2011-03-08	2015-06-24	Sanofi	Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
EP2567959B1 (fr)	2011-09-12	2014-04-16	Sanofi	Dérivés d'amide d'acide 6-(4-hydroxy-phényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
WO2014159392A1 (fr)	2013-03-14	2014-10-02	Dana-Farber Cancer Institute, Inc.	Réactifs de liaison à des bromodomaines et leurs utilisations
WO2014205045A1 (fr) *	2013-06-18	2014-12-24	Downes, Michael	Procédés de traitement de dystrophie musculaire
US9975896B2 (en)	2013-07-25	2018-05-22	Dana-Farber Cancer Institute, Inc.	Inhibitors of transcription factors and uses thereof
RU2016122654A (ru)	2013-11-08	2017-12-14	Дана-Фарбер Кэнсер Инститьют, Инк.	Комбинированная терапия злокачественной опухоли с использованием ингибиторов бромодоменового и экстратерминального (вет) белка
CN105940005A (zh)	2014-01-31	2016-09-14	达纳-法伯癌症研究所股份有限公司	二氮杂环庚烷衍生物及其用途
EP3099677A4 (fr)	2014-01-31	2017-07-26	Dana-Farber Cancer Institute, Inc.	Dérivés de diaminopyrimidine benzènesulfone et leurs utilisations
US10793571B2 (en)	2014-01-31	2020-10-06	Dana-Farber Cancer Institute, Inc.	Uses of diazepane derivatives
JP2017506666A (ja)	2014-02-28	2017-03-09	テンシャセラピューティクス，インコーポレイテッド	高インスリン血症に関連した症状の処置
EP3122872B1 (fr)	2014-03-27	2019-07-03	The Salk Institute for Biological Studies	Compositions et méthodes destinées à traiter le diabète de type 1 et type 2 et autres troubles associés
CN106793775B (zh)	2014-08-08	2020-06-02	达纳-法伯癌症研究所股份有限公司	二氢碟啶酮衍生物及其用途
CN106715437A (zh)	2014-08-08	2017-05-24	达纳-法伯癌症研究所股份有限公司	二氮杂环庚烷衍生物及其用途
KR20170068597A (ko)	2014-10-27	2017-06-19	텐샤 세러퓨틱스 인코포레이티드	브로모도메인 저해제
AU2016225076B2 (en)	2015-02-27	2018-09-13	Salk Institute For Biological Studies	Reprogramming progenitor compositions and methods of use therefore
WO2016201370A1 (fr)	2015-06-12	2016-12-15	Dana-Farber Cancer Institute, Inc.	Thérapie d'association utilisant des inhibiteurs de transcription et des inhibiteurs de kinases
EP3347021A4 (fr)	2015-09-11	2019-07-24	Dana-Farber Cancer Institute, Inc.	Cyano-thiénotriazoloazépines et leurs utilisations
RU2018112953A (ru)	2015-09-11	2019-10-14	Дана-Фарбер Кэнсер Инститьют, Инк.	Ацетамидтиенотриазолодиазепины и пути их применения
WO2017053084A1 (fr) *	2015-09-25	2017-03-30	Salk Institute For Biological Studies	Le récepteur gamma apparenté au récepteur des œstrogènes (erry) améliore et maintient la capacité thermogène de la graisse brune
MX2018006499A (es)	2015-11-25	2018-08-01	Dana Farber Cancer Inst Inc	Inhibidores de bromodominio bivalentes y usos de los mismos.
US11760977B2 (en)	2016-05-25	2023-09-19	Salk Institute For Biological Studies	Compositions and methods for organoid generation and disease modeling

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1525323B1 (fr) *	2001-11-09	2015-01-21	Dana-Farber Cancer Institute, Inc.	Pgc-1beta, un nouvel homologue du pgc-1 et ses utilisations
WO2004015415A1 (fr) *	2002-08-08	2004-02-19	Japan Science And Technology Agency	Methode de criblage de medicament
US20050074765A1 (en) *	2002-10-16	2005-04-07	Blanchard Steven G.	Methods for identifying and using modulators of estrogen related receptor gamma
WO2006130503A2 (fr) *	2005-05-27	2006-12-07	Janssen Pharmaceutica N.V.	Complexes de fragments de peptides errg et utilisation de ceux-ci dans un nouveau medicament

2007
- 2007-05-02 BR BRPI0711174-6A patent/BRPI0711174A2/pt not_active IP Right Cessation
- 2007-05-02 KR KR1020087026812A patent/KR20090005137A/ko not_active Withdrawn
- 2007-05-02 EP EP07783060A patent/EP2015777B1/fr not_active Revoked
- 2007-05-02 CA CA002649701A patent/CA2649701A1/fr not_active Abandoned
- 2007-05-02 DE DE602007008553T patent/DE602007008553D1/de active Active
- 2007-05-02 CN CNA2007800155975A patent/CN101432024A/zh active Pending
- 2007-05-02 RU RU2008147269/14A patent/RU2008147269A/ru not_active Application Discontinuation
- 2007-05-02 MX MX2008014008A patent/MX2008014008A/es not_active Application Discontinuation
- 2007-05-02 AU AU2007248112A patent/AU2007248112A1/en not_active Abandoned
- 2007-05-02 WO PCT/US2007/067971 patent/WO2007131005A2/fr not_active Ceased
- 2007-05-02 US US12/299,256 patent/US20090281191A1/en not_active Abandoned
- 2007-05-02 AT AT07783060T patent/ATE477819T1/de not_active IP Right Cessation
- 2007-05-02 JP JP2009510039A patent/JP2009535425A/ja active Pending

Also Published As

Publication number	Publication date
MX2008014008A (es)	2009-03-25
JP2009535425A (ja)	2009-10-01
US20090281191A1 (en)	2009-11-12
BRPI0711174A2 (pt)	2011-08-23
WO2007131005A3 (fr)	2008-06-19
EP2015777A2 (fr)	2009-01-21
WO2007131005A2 (fr)	2007-11-15
ATE477819T1 (de)	2010-09-15
AU2007248112A1 (en)	2007-11-15
CN101432024A (zh)	2009-05-13
RU2008147269A (ru)	2010-06-10
DE602007008553D1 (de)	2010-09-30
KR20090005137A (ko)	2009-01-12
EP2015777B1 (fr)	2010-08-18

Legal Events

Date	Code	Title	Description
2011-05-02	FZDE	Discontinued

Publication	Publication Date	Title
US20090281191A1 (en)	2009-11-12	Use of organic compounds
Ribas et al.	2016	Skeletal muscle action of estrogen receptor α is critical for the maintenance of mitochondrial function and metabolic homeostasis in females
Clayton et al.	2023	Cellular senescence contributes to large elastic artery stiffening and endothelial dysfunction with aging: amelioration with senolytic treatment
Zhou et al.	2020	Melatonin inhibits glucose-induced apoptosis in osteoblastic cell line through PERK-eIF2α-ATF4 pathway
Li et al.	2010	Vascular insulin resistance in prehypertensive rats: role of PI3-kinase/Akt/eNOS signaling
Baer et al.	1983	Panic attacks and the dexamethasone suppression test
US8058316B2 (en)	2011-11-15	STAT3 inhibiting compositions and methods
Brown et al.	2008	The APOE4 genotype alters the response of microglia and macrophages to 17β-estradiol
CN104080454A (zh)	2014-10-01	用于抑制肌萎缩的方法
Ding et al.	2017	Insulin resistance disrupts the interaction between AKT and the NMDA receptor and the inactivation of the CaMKIV/CREB pathway in minimal hepatic encephalopathy
Consitt et al.	2010	Peroxisome proliferator–activated receptor-γ coactivator-1α overexpression increases lipid oxidation in myocytes from extremely obese individuals
Tanis et al.	2015	The effect of glucose concentration and sodium phenylbutyrate treatment on mitochondrial bioenergetics and ER stress in 3T3-L1 adipocytes
Xiao et al.	2020	Mitochondrial energetic impairment in a patient with late‐onset glutaric acidemia Type 2
JP5901770B2 (ja)	2016-04-13	Ｃｙｐ４ａ阻害剤を有効成分として含有する糖尿病又は脂肪肝の予防又は治療用薬学的組成物。
WO2024030909A1 (fr)	2024-02-08	Biomarqueurs de réponse au traitement d'une composition d'acides aminés dans covid long
Gao et al.	2016	Oxidative stress increases the risk of pancreatic β cell damage in chronic renal hypertensive rats
CN1720051A (zh)	2006-01-11	脂肪调节
WO2010007085A2 (fr)	2010-01-21	Utilisation de composés organiques
US10292980B2 (en)	2019-05-21	GAPDH cascade inhibitor compounds and methods of use and treatment of stress induced disorders including mental illness
US10376484B2 (en)	2019-08-13	Combination of bezafibrate and of resveratrol or resveratrol derivatives for the treatment and prevention of diseases involving a mitochondrial energy dysfunction
Katte et al.	2026	Atypical diabetes subtypes in Black African populations
Tvarijonaviciute et al.	2012	Serum adiponectin concentration in dogs—absence of diurnal variation and lack of effect of feeding and methylprednisolone administration
WO2005085846A1 (fr)	2005-09-15	Diagnostic pour groupe de risques de maladies cardiaques ischémiques
Mann	2021	Unraveling Molecular Mechanisms Responsible for the Healthspan Benefits of 17α-Estradiol, a Lifespan-Extending Compound
AU2017317575B2 (en)	2021-10-14	Treatment of nonalcoholic fatty liver disease